tetano
Editor, Senior Moderator
Sci Rep
. 2024 Jul 22;14(1):16831.
doi: 10.1038/s41598-024-67828-7. Genomic surveillance and vaccine response to the dominant SARS-CoV-2 XBB lineage in Rio Grande do Sul
Bruna Candia Piccoli[SUP] 1 [/SUP], Thais Regina Y Castro[SUP] 1 [/SUP], Luíza Funck Tessele[SUP] 1 [/SUP], Bruna Campestrini Casarin[SUP] 1 [/SUP], Ana Paula Seerig[SUP] 2 [/SUP], Andressa de Almeida Vieira[SUP] 1 [/SUP], Vitor Teles Santos[SUP] 1 [/SUP], Alexandre Vargas Schwarzbold[SUP] 3 [/SUP], Priscila Arruda Trindade[SUP] 4 [/SUP]
Affiliations
The COVID-19 pandemic has been marked by novel viral variants, posing challenges to global public health. Recombination, a viral evolution mechanism, is implicated in SARS-CoV-2's ongoing evolution. The XBB recombinant lineage, known for evading antibody-mediated immunity, exhibits higher transmissibility without increased disease severity. We investigated the prevalence and genomic features of XBB in SARS-CoV-2-positive cases in Rio Grande do Sul (RS), Brazil. We sequenced 357 samples from epidemiological weeks (EW) 47/2022 to 17/2023, and included 389 publicly available sequences. Clinical and epidemiological data were obtained from DATASUS, e-SUS, and SIVEP GRIPE (data recording systems of the Brazilian Ministry of Health). Of these, 143 were classified as XBB and 586 were other Omicron lineages. In March 2023 (EW 10), XBB became dominant, accounting for 83.3% of cases. 97.7% of XBB-infected patients successfully recovered from the infection, with a low mortality rate (2.3%). Even after receiving three vaccine doses and having been previously infected, 59.5% of the patients experienced reinfection with XBB. However, for 54% of the individuals, the interval between their XBB infection and the last vaccine dose exceeded one year, potentially leading to a decline in antibody levels. In addition, we identified 90 mutations in RS circulating XBB, spread throughout the genome, notably in the Spike protein region associated with immune resistance. This study provides insights into the dynamics and impact of a recombinant variant becoming predominant for the first time in the state. Continued surveillance of SARS-CoV-2 genomic evolution is crucial for effective public health management.
Keywords: COVID-19; Genome sequencing; Molecular epidemiology; Recombinant variant.
. 2024 Jul 22;14(1):16831.
doi: 10.1038/s41598-024-67828-7. Genomic surveillance and vaccine response to the dominant SARS-CoV-2 XBB lineage in Rio Grande do Sul
Bruna Candia Piccoli[SUP] 1 [/SUP], Thais Regina Y Castro[SUP] 1 [/SUP], Luíza Funck Tessele[SUP] 1 [/SUP], Bruna Campestrini Casarin[SUP] 1 [/SUP], Ana Paula Seerig[SUP] 2 [/SUP], Andressa de Almeida Vieira[SUP] 1 [/SUP], Vitor Teles Santos[SUP] 1 [/SUP], Alexandre Vargas Schwarzbold[SUP] 3 [/SUP], Priscila Arruda Trindade[SUP] 4 [/SUP]
Affiliations
- PMID: 39039137
- DOI: 10.1038/s41598-024-67828-7
The COVID-19 pandemic has been marked by novel viral variants, posing challenges to global public health. Recombination, a viral evolution mechanism, is implicated in SARS-CoV-2's ongoing evolution. The XBB recombinant lineage, known for evading antibody-mediated immunity, exhibits higher transmissibility without increased disease severity. We investigated the prevalence and genomic features of XBB in SARS-CoV-2-positive cases in Rio Grande do Sul (RS), Brazil. We sequenced 357 samples from epidemiological weeks (EW) 47/2022 to 17/2023, and included 389 publicly available sequences. Clinical and epidemiological data were obtained from DATASUS, e-SUS, and SIVEP GRIPE (data recording systems of the Brazilian Ministry of Health). Of these, 143 were classified as XBB and 586 were other Omicron lineages. In March 2023 (EW 10), XBB became dominant, accounting for 83.3% of cases. 97.7% of XBB-infected patients successfully recovered from the infection, with a low mortality rate (2.3%). Even after receiving three vaccine doses and having been previously infected, 59.5% of the patients experienced reinfection with XBB. However, for 54% of the individuals, the interval between their XBB infection and the last vaccine dose exceeded one year, potentially leading to a decline in antibody levels. In addition, we identified 90 mutations in RS circulating XBB, spread throughout the genome, notably in the Spike protein region associated with immune resistance. This study provides insights into the dynamics and impact of a recombinant variant becoming predominant for the first time in the state. Continued surveillance of SARS-CoV-2 genomic evolution is crucial for effective public health management.
Keywords: COVID-19; Genome sequencing; Molecular epidemiology; Recombinant variant.